Funded Project Details - FY2021
|Title:|| CCN5 Therapy for Triple Negative Breast Cancer|
Sushanta K. Banerjee
||Kansas City, MO
|Congressional District Code:
||Biomedical Laboratory R&D
|| October 2019 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Current therapies for breast cancer (BC) are firmly believed to improve patient survival efficiently. However, one-third of aggressive triple-negative breast cancer (TNBC) patients may relapse more frequently compared to hormone receptor-positive subtypes, and patients may eventually develop the distant metastatic disease and drug resistance. There are no targeted therapies currently available for invasive and metastatic diseases, indicating a dire need for improved therapy. We revealed that CCN...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.